is mounjaro a glp-1 agonist Ophthalmic Complications Observed After Use of Agonists GLP-1 Agonists - FAQ —

The FDA approved sitagliptin, the first DPP-4i on the market, in 2006 and shortly after, numerous additional DPP-4i received market clearance

NAION is a rare but severe condition that can reduce blood flow to the optic nerve and result in partial or complete blindness

It measures three maternal serum markers: Alpha-Fetoprotein (AFP), Human Chorionic Gonadotropin (hCG), and Unconjugated Estriol (uE3)

Considering the growing burden of obesity and diabetes, there has been a rise in the need for safe and effective medications

moreover it is still unclear whether GIP has direct, insulin independent, metabolic effects on adipose tissue

Dual-pathway therapies that target both GLP-1 and GIP receptors sit alongside better-known GLP-1-focused options